Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Director Sells $802,872.00 in Stock

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Director Bonnie L. Bassler sold 756 shares of the stock in a transaction on Monday, June 24th. The stock was sold at an average price of $1,062.00, for a total transaction of $802,872.00. Following the completion of the transaction, the director now directly owns 1,382 shares in the company, valued at approximately $1,467,684. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $1,050.86 on Friday. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $684.80 and a fifty-two week high of $1,081.17. The stock’s 50 day simple moving average is $978.05 and its two-hundred day simple moving average is $948.28. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.51 and a current ratio of 5.27. The stock has a market cap of $115.79 billion, a price-to-earnings ratio of 31.04, a PEG ratio of 2.21 and a beta of 0.13.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share for the quarter, missing the consensus estimate of $8.46 by ($0.49). The firm had revenue of $3.15 billion for the quarter, compared to the consensus estimate of $3.19 billion. Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. As a group, analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.23 earnings per share for the current fiscal year.

Institutional Trading of Regeneron Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the business. West Paces Advisors Inc. increased its stake in shares of Regeneron Pharmaceuticals by 575.0% during the first quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 23 shares in the last quarter. Crewe Advisors LLC bought a new position in Regeneron Pharmaceuticals during the 1st quarter valued at approximately $28,000. Fortitude Family Office LLC purchased a new position in Regeneron Pharmaceuticals during the fourth quarter valued at $31,000. MCF Advisors LLC raised its stake in Regeneron Pharmaceuticals by 50.0% during the fourth quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 12 shares during the last quarter. Finally, Criterion Capital Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter worth $37,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on REGN. StockNews.com downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, April 30th. Argus raised their price objective on Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the company a “buy” rating in a report on Tuesday. Bank of America upped their target price on Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an “underperform” rating in a research note on Friday, April 12th. Evercore ISI began coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, May 14th. They set an “outperform” rating and a $1,150.00 price target on the stock. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $925.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Friday, May 3rd. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $1,015.91.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.